AEMD - רווח נקי למניה (EPS TTM) Aethlon

Aethlon Medical (AEMD) develops innovative filters for blood pathogen clearance, yet slow trial recruitment and a revenue deficit create a risk of capital dilution. The trailing 12-month EPS reflects current financial dynamics, with the latest parameter standing at -24.91. As it competes for hospital protocols, the company faces pressure from global medtech behemoths within the narrow niche of therapeutic filtration.

Earnings per share (EPS) reflects the owner's share in the company's bottom line. By analyzing the TTM earnings per share distribution, an investor can gauge the efficiency of capital generation over the year. The metric is calculated by dividing total income minus expenses by the number of outstanding common shares. For Aethlon Medical (AEMD), this indicator demonstrates the transition stage from Hemopurifier development to commercial monetization. Growth in EPS would confirm the market success of innovations in the field of extracorporeal blood purification.